Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
Oct
31
NAYZILAM® (midazolam) Results Published in Epilepsy & Behavior Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters
Oct
18
BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
Oct
18
Evolving Expectations for Dermatological Conditions
Oct
17
UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis
Oct
17
Steadfast Towards Our Ambition to Create a UCB Rare Disease Portfolio
Oct
12
Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa